| P2093 | author name string | Shuo Ma | |
| | Erin M Pettijohn | |
| P2860 | cites work | Long-term remissions after FCR chemoimmunotherapy in previously untreated patients with CLL: updated results of the CLL8 trial | Q39005118 |
| | Outcomes of CLL patients treated with sequential kinase inhibitor therapy: a real world experience. | Q39416260 |
| | First-line chemoimmunotherapy with bendamustine and rituximab versus fludarabine, cyclophosphamide, and rituximab in patients with advanced chronic lymphocytic leukaemia (CLL10): an international, open-label, randomised, phase 3, non-inferiority tri | Q40662825 |
| | Outcomes of patients with chronic lymphocytic leukemia after discontinuing ibrutinib | Q41601558 |
| | Phase I study of single-agent CC-292, a highly selective Bruton's tyrosine kinase inhibitor, in relapsed/refractory chronic lymphocytic leukemia | Q42399825 |
| | Ibrutinib antagonizes rituximab-dependent NK cell-mediated cytotoxicity | Q42401591 |
| | Genetic analysis of chemoresistance in primary murine lymphomas. | Q43422059 |
| | Ibrutinib treatment affects collagen and von Willebrand factor-dependent platelet functions. | Q54316160 |
| | Ibrutinib increases the risk of atrial fibrillation, potentially through inhibition of cardiac PI3K-Akt signaling. | Q55069337 |
| | Obinutuzumab plus Chlorambucil in Patients with CLL and Coexisting Conditions | Q56657194 |
| | Obinutuzumab as frontline treatment of chronic lymphocytic leukemia: updated results of the CLL11 study | Q86625695 |
| | TP53 mutation and survival in chronic lymphocytic leukemia | Q27851577 |
| | Incidence of haematological malignancy by sub-type: a report from the Haematological Malignancy Research Network | Q28252000 |
| | An open-label phase 2 trial of entospletinib (GS-9973), a selective spleen tyrosine kinase inhibitor, in chronic lymphocytic leukemia | Q28257366 |
| | Idelalisib and rituximab in relapsed chronic lymphocytic leukemia | Q28306347 |
| | Cancer statistics, 2016 | Q29547383 |
| | Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia | Q29620690 |
| | Bendamustine in combination with rituximab for previously untreated patients with chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group | Q33402713 |
| | Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomised, double-blind, phase 3 study | Q33428297 |
| | Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study | Q33432228 |
| | Idelalisib, an inhibitor of phosphatidylinositol 3-kinase p110δ, for relapsed/refractory chronic lymphocytic leukemia | Q34009003 |
| | Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia | Q34052075 |
| | Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial | Q34141305 |
| | Safety and activity of ibrutinib plus rituximab for patients with high-risk chronic lymphocytic leukaemia: a single-arm, phase 2 study | Q34240404 |
| | Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia | Q34504188 |
| | Three-year follow-up of treatment-naïve and previously treated patients with CLL and SLL receiving single-agent ibrutinib | Q35450520 |
| | Second cancers in patients with chronic lymphocytic leukemia who received frontline fludarabine, cyclophosphamide and rituximab therapy: distribution and clinical outcomes | Q35625192 |
| | Etiology of Ibrutinib Therapy Discontinuation and Outcomes in Patients With Chronic Lymphocytic Leukemia | Q35903984 |
| | Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia | Q36888218 |
| | The BCL2 selective inhibitor venetoclax induces rapid onset apoptosis of CLL cells in patients via a TP53-independent mechanism. | Q37035832 |
| | Idelalisib given front-line for treatment of chronic lymphocytic leukemia causes frequent immune-mediated hepatotoxicity. | Q37097096 |
| | Treatment of elderly patients with chronic lymphocytic leukemia | Q37386705 |
| | Patterns of resistance to B cell-receptor pathway antagonists in chronic lymphocytic leukemia and strategies for management | Q38659524 |
| P433 | issue | 1 | |
| P921 | main subject | lymphocyte | Q715347 |
| | chronic lymphocytic leukemia | Q1088156 |
| P304 | page(s) | 20-28 | |
| P577 | publication date | 2017-02-02 | |
| P1433 | published in | Current hematologic malignancy reports | Q26842233 |
| P1476 | title | Targeted Therapy in Chronic Lymphocytic Leukemia (CLL). | |
| P478 | volume | 12 | |